Evidence map›Paper›PMID 41715079›Full record

ArticleBMC endocrine disorders2026

Copeptin as a dual biomarker in type 2 diabetes: association with glycemic control and diabetic kidney disease.

Nehal Kamal Rakha, Ahmed Fayed, Shady A Ramiz, Eman ElSayed, Sameh A Al-Dawy, Fadia Moris Bolis, Ahmed Fathy, Sameh Abouzeid, Rasha Ahmed Darwish, Mohammed Gomaa and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nehal Kamal RakhaNephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Ahmed FayedNephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt. drfayed@kasralainy.edu.eg.
Shady A RamizNephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Eman ElSayedNephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Sameh A Al-DawyNephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Fadia Moris BolisNephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Ahmed FathyNephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Sameh AbouzeidNephrology Department, Theodor Bilharz Research Institute, Cairo, Egypt.
Rasha Ahmed DarwishNephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Mohammed GomaaEndocrinology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.
Hend A ElsheimyEndocrinology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic kidney disease and end-stage renal disease are significantly contributed by diabetes mellitus (DM), especially diabetes mellitus type 2 (T2DM). A stable surrogate marker of vasopressin, the serum copeptin, has become a potential biomarker of poor glycemic control and diabetic kidney disease (DKD). The research objective is to estimate the usefulness of the serum copeptin as a marker of glycemic status and its correlation with DKD in patients with T2DM.

methodsThis cross-sectional study was conducted on 60 participants at Cairo University Hospital between 2021 and 2022. Participants were divided into 40 T2DM patients (26 males, 14 females; mean age 52.62 ± 9.7 years) and 20 healthy controls. Diabetic patients were further categorized into controlled (HbA1c ≤ 7%, n = 18) and uncontrolled (HbA1c > 7%, n = 22) subgroups. Clinical evaluation, biochemical tests, and serum copeptin levels (measured via ELISA) were analyzed. Cairo university, Faculty of Medicine, Ethical approval: N-247-2023.

resultsSerum copeptin levels were significantly higher in diabetic patients compared to controls (p < 0.001), and in uncontrolled vs. controlled diabetics (p < 0.001). Copeptin positively correlated with fasting glucose, HbA1c, serum creatinine, and urinary protein, and negatively with eGFR. ROC analysis identified copeptin as a sensitive marker for both poor glycemic control at a cut off value > 3452 pg/mL (AUC 0.925) and DKD at a cut off vlue > 370 pg/mL (AUC 0.94), both with high sensitivity and specificity.

conclusionThe level of serum copeptin correlates positively with poor glycemic status as well as DKD among T2DM patients. It can be an effective, non-invasive biomarker used in early diagnosis and risk stratification of diabetic complications. CLINICAL

trial registrationNot applicable.

Indexed as

BiomarkersDiabetes Mellitus, Type 2Diabetic NephropathiesGlycemic ControlGlycopeptidesAdultBlood GlucoseCase-Control StudiesCross-Sectional StudiesFemaleFollow-Up StudiesGlycated HemoglobinHumansMaleMiddle AgedPrognosisBiomarkersBlood GlucosecopeptinsGlycated HemoglobinGlycopeptidesCopeptinDiabetic kidney diseaseGlycemic controlType 2 diabetes

Identifiers

PMID41715079
PMCPMC13020287

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.